Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection

Antiviral Research

Volumn 100, Issue 2, 2013, Pages 321-327

  Reitsma, Justin M ^a   Terhune, Scott S ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

HCMV; Human cytomegalovirus; Maribavir; STAT3; STAT3 inhibitor; UL97

Indexed keywords

4 [[(4 METHYLPHENYL)SULFONYLOXY]ACETAMIDO]SALICYLIC ACID; BENZIMIDAVIR; CASPASE; S 3I 201; STAT3 PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA; AMINOSALICYLIC ACID DERIVATIVE; ANTIVIRUS AGENT; BENZENESULFONIC ACID DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; RIBONUCLEOSIDE; STAT3 INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DNA SYNTHESIS; DRUG POTENTIATION; FIBROBLAST; GENE EXPRESSION; IN VITRO STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HUMAN CYTOMEGALOVIRUS; PHYSIOLOGY; UL97; VIRUS REPLICATION;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; MUSHROOM BACILLIFORM VIRUS;

HCMV; HUMAN CYTOMEGALOVIRUS; MARIBAVIR; STAT3; STAT3 INHIBITOR; UL97;

AMINOSALICYLIC ACIDS; ANTIVIRAL AGENTS; BENZENESULFONATES; BENZIMIDAZOLES; CELL LINE; CYTOMEGALOVIRUS; DRUG SYNERGISM; HUMANS; RIBONUCLEOSIDES; STAT3 TRANSCRIPTION FACTOR; VIRUS REPLICATION;

EID: 84885352457     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.09.011     Document Type: Article

References (40)

1. N. Baryawno, A. Rahbar, N. Wolmer-Solberg, C. Taher, J. Odeberg, A. Darabi, Z. Khan, B. Sveinbjornsson, O.M. FuskevAg, L. Segerstrom, M. Nordenskjold, P. Siesjo, P. Kogner, J.I. Johnsen, and C. Soderberg-Naucler Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target J. Clin. Invest. 121 2011 4043 4055
2. I.V. Bijnsdorp, E. Giovannetti, and G.J. Peters Analysis of drug interactions Methods Mol. Biol. 731 2011 421 434
3. K.K. Biron Antiviral drugs for cytomegalovirus diseases Antiviral Res. 71 2006 154 163
4. W.A. Bresnahan, T. Albrecht, and E.A. Thompson The cyclin E promoter is activated by human cytomegalovirus 86-kDa immediate early protein J. Biol. Chem. 273 1998 22075 22082
5. W. Britt Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease Curr. Top. Microbiol. Immunol. 325 2008 417 470
6. W. Brune Inhibition of programmed cell death by cytomegaloviruses Virus Res. 157 2011 144 150
7. Z. Chen, E. Knutson, A. Kurosky, and T. Albrecht Degradation of p21cip1 in cells productively infected with human cytomegalovirus J. Virol. 75 2001 3613 3625
8. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 58 2006 621 681
9. T.C. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 70 2010 440 446
10. S. Chou, and G.I. Marousek Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus Antimicrob. Agents Chemother. 50 2006 3470 3472
11. S. Chou, L.C. Van Wechel, and G.I. Marousek Effect of cell culture conditions on the anticytomegalovirus activity of maribavir Antimicrob. Agents Chemother. 50 2006 2557 2559
12. R.B. Gill, S.H. James, and M.N. Prichard Human cytomegalovirus UL97 kinase alters the accumulation of CDK1 J. Gen. Virol. 93 2012 1743 1755
13. J.M. Gottwein, S.B. Jensen, Y.P. Li, L. Ghanem, T.K. Scheel, S.B. Serre, L. Mikkelsen, and J. Bukh Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses Antimicrob. Agents Chemother. 57 2013 1291 1303
14. M. Hakki, and S. Chou The biology of cytomegalovirus drug resistance Curr. Opin. Infect. Dis. 24 2011 605 611
15. S. Hamirally, J.P. Kamil, Y.M. Ndassa-Colday, A.J. Lin, W.J. Jahng, M.C. Baek, S. Noton, L.A. Silva, M. Simpson-Holley, D.M. Knipe, D.E. Golan, J.A. Marto, and D.M. Coen Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress PLoS Pathog. 5 2009 e1000275
16. L. Hertel, S. Chou, and E.S. Mocarski Viral and cell cycle-regulated kinases in cytomegalovirus-induced pseudomitosis and replication PLoS Pathog. 3 2007 e6
17. A.J. Hume, J.S. Finkel, J.P. Kamil, D.M. Coen, M.R. Culbertson, and R.F. Kalejta Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function Science 320 2008 797 799
18. P.A. Johnston, and J.R. Grandis STAT3 signaling: anticancer strategies and challenges Mol. Interv. 11 2011 18 26
19. J.P. Kamil, A.J. Hume, I. Jurak, K. Munger, R.F. Kalejta, and D.M. Coen Human papillomavirus 16 E7 inactivator of retinoblastoma family proteins complements human cytomegalovirus lacking UL97 protein kinase Proc. Natl. Acad. Sci. USA 106 2009 16823 16828
20. E. Littler, A.D. Stuart, and M.S. Chee Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir Nature 358 1992 160 162
21. D.B. Liu, G.Y. Hu, G.X. Long, H. Qiu, Q. Mei, and G.Q. Hu Celecoxib induces apoptosis and cell-cycle arrest in nasopharyngeal carcinoma cell lines via inhibition of STAT3 phosphorylation Acta Pharmacol. Sin. 33 2012 682 690
22. F.M. Marty, P. Ljungman, G.A. Papanicolaou, D.J. Winston, R.F. Chemaly, L. Strasfeld, J.A. Young, T. Rodriguez, J. Maertens, M. Schmitt, H. Einsele, A. Ferrant, J.H. Lipton, S.A. Villano, H. Chen, M. Boeckh Maribavir -300 Clinical Study, G. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial Lancet Infect. Dis. 11 2011 284 292
23. B. Mercorelli, D. Lembo, G. Palu, and A. Loregian Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives Pharmacol. Ther. 131 2011 309 329
24. M. Michaelis, C. Paulus, N. Loschmann, S. Dauth, E. Stange, H.W. Doerr, M. Nevels, and J. Cinatl Jr. The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication Cell. Mol. Life Sci. 68 2011 1079 1090
25. D.P. Mitchell, J.P. Savaryn, N.J. Moorman, T. Shenk, and S.S. Terhune Human cytomegalovirus UL28 and UL29 open reading frames encode a spliced mRNA and stimulate accumulation of immediate-early RNAs J. Virol. 83 2009 10187 10197
26. U. Nayar, P. Lu, R.L. Goldstein, J. Vider, G. Ballon, A. Rodina, T. Taldone, H. Erdjument-Bromage, M. Chomet, R. Blasberg, A. Melnick, L. Cerchietti, G. Chiosis, Y.L. Wang, and E. Cesarman Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies Blood 2013 [Epub ahead of print]
27. C.M. O'Connor, and T. Shenk Human cytomegalovirus pUS27 G protein-coupled receptor homologue is required for efficient spread by the extracellular route but not for direct cell-to-cell spread J. Virol. 85 2011 3700 3707
28. M.N. Prichard Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir Rev. Med. Virol. 19 2009 215 229
29. J.M. Reitsma, J.P. Savaryn, K. Faust, H. Sato, B.D. Halligan, and S.S. Terhune Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest Cell Host Microbe 9 2011 103 114
30. J.M. Reitsma, H. Sato, M. Nevels, S.S. Terhune, and C. Paulus Human cytomegalovirus IE1 protein disrupts interleukin-6 signaling by sequestering STAT3 in the nucleus J. Virol. 87 2013 10763 10776
31. V. Sanchez, and D.H. Spector Subversion of cell cycle regulatory pathways Curr. Top. Microbiol. Immunol. 325 2008 243 262
32. V. Sanchez, A.K. McElroy, and D.H. Spector Mechanisms governing maintenance of Cdk1/cyclin B1 kinase activity in cells infected with human cytomegalovirus J. Virol. 77 2003 13214 13224
33. N. Sen, X. Che, J. Rajamani, L. Zerboni, P. Sung, J. Ptacek, and A.M. Arvin Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis Proc. Natl. Acad. Sci. USA 109 2012 600 605
34. K. Siddiquee, S. Zhang, W.C. Guida, M.A. Blaskovich, B. Greedy, H.R. Lawrence, M.L. Yip, R. Jove, M.M. McLaughlin, N.J. Lawrence, S.M. Sebti, and J. Turkson Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity Proc. Natl. Acad. Sci. USA 104 2007 7391 7396
35. D.R. Snydman Why did maribavir fail in stem-cell transplants? Lancet Infect Dis. 11 2011 255 257
36. V. Sullivan, C.L. Talarico, S.C. Stanat, M. Davis, D.M. Coen, and K.K. Biron A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells Nature 359 1992 85
37. S.S. Terhune, N.J. Moorman, I.M. Cristea, J.P. Savaryn, C. Cuevas-Bennett, M.P. Rout, B.T. Chait, and T. Shenk Human cytomegalovirus UL29/28 protein interacts with components of the NuRD complex which promote accumulation of immediate-early RNA PLoS Pathog. 6 2010 e1000965
38. O.A. Timofeeva, N.I. Tarasova, X. Zhang, S. Chasovskikh, A.K. Cheema, H. Wang, M.L. Brown, and A. Dritschilo STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain Proc. Natl. Acad. Sci. USA 110 2013 1267 1272
39. F. Yang, T.E. Van Meter, R. Buettner, M. Hedvat, W. Liang, C.M. Kowolik, N. Mepani, J. Mirosevich, S. Nam, M.Y. Chen, G. Tye, M. Kirschbaum, and R. Jove Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas Mol. Cancer Ther. 7 2008 3519 3526
40. H. Yu, D. Pardoll, and R. Jove STATs in cancer inflammation and immunity: a leading role for STAT3 Nat. Rev. Cancer 9 2009 798 809